Hubei Hengdi Pharmaceutical

Hubei Hengdi Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and finished dosage forms. The company is globally recognized as one of the top three manufacturers of ibuprofen, maintaining a significant share of the international market for non-steroidal anti-inflammatory drugs (NSAIDs). Beyond its core analgesic portfolio, which includes naproxen and flurbiprofen, Hengdi produces specialized cardiovascular treatments such as methyldopa. Headquartered in Jingmen, Hubei Province, the company operates advanced manufacturing facilities that comply with international GMP standards, serving major pharmaceutical clients across Europe, North America, and Asia. Hengdi Pharmaceutical is publicly listed on the Shenzhen Stock Exchange and continues to expand its capacity in both chemical synthesis and finished drug product manufacturing.